Successful treatment with rituximab of one patient with CANOMAD neuropathy.
We report a successful treatment with rituximab in a patient with CANOMAD neuropathy resistant to previous therapy. The titers of anti-disialosyl antibodies were decreased 3 months after the beginning of the treatment and the sensory ataxia clearly improved after 9 months of therapy.
Delmont
Emilien
E
Jeandel
P Y
PY
Hubert
A M
AM
Marcq
L
L
Boucraut
J
J
Desnuelle
C
C
D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000954:Antigens, Surface / Q000276:immunology; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D007155:Immunologic Factors / Q000627:therapeutic use*; D009844:Oligosaccharides / Q000276:immunology; D009886:Ophthalmoplegia / Q000150:complications / Q000188:drug therapy*; D011129:Polyradiculoneuropathy / Q000150:complications / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000954:Antigens, Surface; D007075:Immunoglobulin M; D007155:Immunologic Factors; D009844:Oligosaccharides; C108031:disialosyl-T antigen, human; D000069283:Rituximab